The Daily

A Curated Briefing

---

Biotech & Pharma

FDA Calendar

Four High-Stakes PDUFA Decisions Land This Month

The FDA will rule on Kresladi (Rocket Pharma's gene therapy for LAD-I, second attempt), LNTH-2501 (Lantheus' radiopharmaceutical, March 29), Reproxalap (third filing for dry eye disease), and Linerixibat (bile acid transporter inhibitor). Kresladi represents the only curative option besides allogeneic HSCT for leukocyte adhesion deficiency. Investors are watching closely—Rocket shares closed Friday at $3.27, up 0.62%. The cluster of decisions could reshape small-cap biotech valuations mid-quarter.

RTT News · PDUFA Tracker · March 2026

Obesity

Lilly Orforglipron NDA Filing Imminent

Eli Lilly's once-daily oral GLP-1 pill for obesity and type 2 diabetes is expected to reach the FDA in late March, setting up a potential approval by year-end. If successful, orforglipron could challenge Novo Nordisk's oral semaglutide (Wegovy pill) before it even launches widely in the U.S.

PharmaVoice · Obesity Pipeline

M&A

Biotech Rally Faces Valuation Test

The sector's 2025 resurgence has left some biotechs trading at "bloated valuations," warn RBC analysts. Crowding into obesity, oncology, and rare disease could make 2026 M&A harder to justify. A run of negative readouts or FDA setbacks would deflate the rally quickly.

BioPharma Dive · Market Outlook

---

Science / Immuno-Oncology

Landmark Study

Blood Advances

Bispecific Antibodies After CAR-T Failure: Real-World Outcomes in DLBCL

The ABC consortium tracked patients with large B-cell lymphoma who received bispecific antibodies (bsAbs) after CAR-T relapse. Response rates were modest but durable in a subset, offering a lifeline for heavily pre-treated patients who exhausted cellular therapy options. The study underscores bsAbs' role as salvage therapy—not a replacement for CAR-T, but a critical bridge to transplant or clinical trials. This shifts the sequencing paradigm: CAR-T first, then bsAbs if needed.

Blood Advances · Jan 13, 2026 · ABC Consortium

Study

Blood Advances

Ibrutinib Exposure Boosts CAR-T Efficacy in MCL

Analysis of the ZUMA-2 trial reveals that prior ibrutinib exposure correlates with improved CAR-T response rates in mantle cell lymphoma. The BTK inhibitor may "prime" the tumor microenvironment, making it more receptive to brexucabtagene autoleucel.

Blood Advances · Feb 24, 2026 · PubMed

Study

Blood

CD4 CAR-T for HIV Fails to Control Viremia in Primates

Antigen-boosted CD4 CAR-T cells showed promise in vitro but failed to expand or suppress HIV in multiple nonhuman primate models. The results highlight the complexity of translating CAR-T success from oncology to chronic infections.

Blood · Feb 24, 2026 · PubMed

Study

Blood Advances

Relmacabtagene (CD19 CAR-T) Phase 2 Results in Chinese MCL Patients

Blood Advances · Feb 24, 2026 · Multicenter

Review

PMC

Bispecific Antibodies: Unleashing a New Era in Oncology Treatment

PMC · Review · ImmTAC Platform

---

AI & Technology

Analysis

Google and OpenAI Employees Rally Behind Anthropic's Pentagon Red Lines

Nearly 50 OpenAI and 175 Google employees signed an open letter urging their executives to reject Pentagon demands that Anthropic refused: no mass surveillance of Americans, no fully autonomous weaponry. The letter accuses the Defense Department of "divide and conquer" tactics, pressuring rivals to undercut Anthropic's ethical stance. This marks a rare moment of cross-company solidarity in AI—and a challenge to leaders who've historically prioritized government contracts over internal dissent.

TechCrunch · Feb 27, 2026 · Open Letter

Policy

Pentagon Approves OpenAI Safety Red Lines After Dumping Anthropic

After Anthropic walked away from a classified network deal, the Pentagon agreed to OpenAI's safety guardrails—suggesting the DoD can meet ethical standards when forced. The timing raises questions: did internal pressure work, or was this always negotiable?

Axios · Feb 27, 2026

Analysis

The Trap Anthropic Built for Itself

TechCrunch's Max Tegmark argues that Anthropic (and rivals) sowed the seeds of this crisis by resisting regulation for years. "They promised to govern themselves responsibly. Now they're shocked the government wants control."

TechCrunch · Feb 28, 2026 · Op-Ed

---

NBA News

Breaking

Pistons Extend League-Best Record to 45-14 With Win Over Magic

Cade Cunningham posted 29 points and 11 assists as the Detroit Pistons defeated Orlando 106-92 on Sunday, marking their sixth consecutive road victory. Detroit now leads the NBA at 45-14, ahead of the Thunder (47-15) and Timberwolves (38-23). Tobias Harris added 23 points. The Pistons' transformation from perennial lottery team to title contender is the league's most stunning storyline of 2026.

ESPN · March 1, 2026 · Recap

Recap

Bulls Dominate Bucks 120-97 in Upset Win

Chicago (25-36) crushed Milwaukee 120-97, handing the Bucks (26-33) their 19th road loss. The lopsided result highlights Milwaukee's late-season struggles despite retaining Giannis at the trade deadline.

ESPN · March 1, 2026

Recap

Thunder Improve to 47-15 With Win Over Mavericks

Oklahoma City beat Dallas 100-87, maintaining second place in the West. The Thunder's acquisition of Jared McCain at the deadline continues to pay dividends as they position for a top-two seed.

ESPN · March 1, 2026

---

Travel

Destination

Italy in March: The Sweet Spot Between Carnival and Easter

Venice just wrapped Carnival; Easter crowds are still weeks away. March offers moderate prices, low tourist numbers, and pleasant (if unpredictable) weather. Mama Loves Italy recommends a rowing class on the Venetian canals ("so much nicer than a gondola ride") and food tours through Rialto Market and traditional bacari. Florence and Rome remain accessible, with shorter museum queues and restaurant availability. Book now—prices tick up as April approaches.

Mama Loves Italy · Updated Feb 2026

Destination

Why 2026 Is the Year to Visit Venice

Condé Nast Traveler highlights new hotels, a hyperlocal food scene, and the return of the Biennale Arte (May 9–Nov 22) as reasons to prioritize Venice this year. Day-tripper fees help fund infrastructure while preserving the city's character.

Condé Nast Traveler · Jan 2026

Destination

Puglia: Italy's Budget Alternative to Tuscany

Located in the "heel of Italy's boot," Puglia offers 800km of coastline, UNESCO sites, and prices 30-40% lower than Tuscany. Ideal base: Ostuni, the "White City" overlooking the Itria Valley.

Odynovo Tours · 2026 Guide

---

Wien für Kinder

Event

Science Busters for Kids — Orpheum, März 2026

Eventfinder Wien · Ab 7 Jahren

Event

Waldseilpark Kahlenberg — Frühlingseröffnung

1000things · Outdoor-Abenteuer

Event

Wienxtra Kinder-Workshops: 2.–8. März

Wienxtra · Gratis, ohne Anmeldung

---

Wien – Kultur & Essen

Neueröffnung

Carioca Bringt Brasilianisches Comfort Food in die Hamburgerstraße

Pão de Queijo, Feijoada, über 20 Cachaças—und ein Garten, der im Sommer zur Copacabana wird. Die neue Carioca-Location setzt auf aufwendig zubereitetes brasilianisches Comfort Food mit kompakter Karte. Natürlich dürfen Caipirinhas nicht fehlen, ergänzt durch Event-Abende und eine Stimmung, die sich eher nach Rio bei Nacht als nach grauem Wiener Alltag anfühlt. Reservierung empfohlen.

Goodnight.at · März 2026

Neueröffnung

Bar Alexandra: Aperitivo-Kultur als Tagesbar

Roberto Pavlović Hariwijadi, bekannt aus Wiens Barszene, mixt in der Bar Alexandra seine Signature Drinks. Das Konzept: italienische Aperitivo-Kultur, ganztags geöffnet.

Vienna Meeting · 2026

Event

Weltfrauentag 8. März: Fokus auf Wiens Gastro-Szene

Rund um den 8. März stehen Frauen in Wiens Gastronomie im Mittelpunkt: Special-Menüs, WinzerINNEN-Weinbegleitungen, und Events, die die weibliche Kreativität der Szene feiern.

1000things · März 2026